摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

9-fluoro-11β,21-dihydroxypregna-1,4,16-triene-3,20-dione | 61618-63-1

中文名称
——
中文别名
——
英文名称
9-fluoro-11β,21-dihydroxypregna-1,4,16-triene-3,20-dione
英文别名
Desoxymetasone Impurity A;(8S,9R,10S,11S,13S,14S)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,11,12,14,15-hexahydro-6H-cyclopenta[a]phenanthren-3-one
9-fluoro-11β,21-dihydroxypregna-1,4,16-triene-3,20-dione化学式
CAS
61618-63-1
化学式
C21H25FO4
mdl
——
分子量
360.426
InChiKey
UAEUTSQWOUBCLN-XRYUJSLGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    536.2±50.0 °C(Predicted)
  • 密度:
    1.31±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿(轻微)、甲醇(轻微、超声处理)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    74.6
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 一种甾体21位羟基氯代或溴代方法
    申请人:天津药业研究院股份有限公司
    公开号:CN109206466B
    公开(公告)日:2022-08-09
    本发明公开了一种甾体21位羟基代或代方法,以式A化合物为起始物,在SO2存在下,通过与代或代试剂反应制备式B化合物。本工艺条件温和,环境友好,所用试剂易得,易操作,成本低,收率高,适合工业化大生产。
  • Steroidal (16.alpha.,17-d)cyclohexenes
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US03944584A1
    公开(公告)日:1976-03-16
    A series of novel steroidal[ 16.alpha., 17-d]cyclohexenes having a 9-fluoro group is disclosed herein for use as anti-inflammatory agents.
    本文披露了一系列具有9-基的新型类固醇[16.alpha.,17-d]环己烯,用作抗炎药物。
  • 16.alpha.-ARYLCARBONYLPREGNENES
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US03976638A1
    公开(公告)日:1976-08-24
    Topical and systemic anti-inflammatory activity is exhibited by steroids having the formula ##SPC1## And the 1,2-dehydro derivatives thereof, wherein R.sub.1 is phenyl, naphthyl, or substituted phenyl or naphthyl.
    具有以下式子##SPC1##和其1,2-去氢衍生物的类固醇表现出局部和全身抗炎活性,其中R.sub.1是苯基,基或取代苯基或基。
  • New Steroidal Antiinflammatory Antedrugs: Steroidal [16.alpha.,17.alpha.-d]-3'-Carbethoxyisoxazolines
    作者:Taesoo Kwon、Ann S. Heiman、Ebenezer T. Oriaku、Kyoungjin Yoon、Henry J. Lee
    DOI:10.1021/jm00006a026
    日期:1995.3
    Novel steroidal antiinflammatory antedrugs, 11 beta,20-dihydroxy-3,20-dioxo-3'-(ethoxycarbonyl)-isoxazolino[16,17-d]pregna-1,4-diene (2a) and 9-fluoro-11 beta,20-dihydroxy-3,20-dioxo-3'-ethoxy-carbonylisoxazolino[16,17-d]pregna-1,4-diene (2b) were prepared in 97% yield via 1,3-dipolar cycloaddition of carbethoxyformonitrile (CEFNO) to 11 beta,21-dihydroxy-3,20-dioxopregna-1,4,16-triene (1a) and 11 beta,21-dihydroxy-3,20-dioxo-9-fluoropregna-1,4,16-triene(1b), respectively, which were prepared via five steps from prednisolone and 9-fluoroprednisolone, respectively. The treatment of steroids 2a and 2b with acetic anhydride in pyridine led to the corresponding 21-acetates 3a and 3b, respectively, in 95% yield. Dose-response profiles of the croton oil-induced ear edema bioassay in rats were used to calculate the following ID50 values (nmol/ear resulting in a 50% reduction of edema): prednisolone (P), 540 nmol; 2b, 135 nmol; and 3b, 101 nmol. Inhibition of edema did not exceed 50% following application of either 2a or 3a. Relative potency calculations indicated that 2b was 4-fold and 3b 5.3-fold more potent than the parent compound P when applied topically. No significant adverse systemic effects were seen following treatments with 3b. These results suggest that C-9-fluorination, side-chain hydroxy group esterification, and [16 alpha,17 alpha-d]-3'-carbethoxyisoxazoline additions to the conventional steroid P improve topical antiinflammatory activity without concomitant increases in adverse systemic activity.
  • US3944584A
    申请人:——
    公开号:US3944584A
    公开(公告)日:1976-03-16
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B